How does InvestorMatch.Pro work?

Upload your pitch deck, and our AI reads it to extract key signals about your startup's stage, sector, traction, and team. The platform then searches the internet for active venture capital investors who match those signals, returning a ranked list of the 20 best-fit investors to approach.

Is InvestorMatch.Pro free?

InvestorMatch.Pro has a free tier available. Upload your deck and get AI analysis at no cost. You only pay when you want to unlock your full personalized investor recommendations.

What types of investors does InvestorMatch.Pro find?

InvestorMatch.Pro focuses on venture capital investors across stages (pre-seed, seed, Series A, Series B) and sectors including SaaS, AI/ML, fintech, healthcare, marketplaces, consumer, and climate tech.

Who created InvestorMatch.Pro?

InvestorMatch.Pro was created by Martin Tobias, a venture capitalist at Incisive Ventures who has made 75+ pre-seed investments over 5 years and was an early investor in DocuSign. He built it as a resource for founders who lack warm introductions to VCs.

How is this different from other investor matching tools?

InvestorMatch.Pro is built by an active VC, not a marketplace. It analyzes your actual pitch deck rather than asking you to fill out a form, and it uses AI to search the live internet for investors rather than relying on a static database.

What stage does Biolumina Ventures invest at?

Biolumina Ventures invests at Pre-Seed, Seed stages.

What sectors does Biolumina Ventures invest in?

Biolumina Ventures invests in Healthcare, Other, AI / ML, Developer Tools.

How much capital does Biolumina Ventures manage?

InvestorMatch does not have a recorded AUM figure for Biolumina Ventures.

Where is Biolumina Ventures located?

Biolumina Ventures is based in Austin, TX.

Biolumina Ventures

Austin, TXWebsite

Biolumina Ventures is a Pre-Seed, Seed venture capital firm based in Austin, TX investing in Healthcare, Other, AI / ML. The firm typically writes $500K–$3.0M checks and has 6 portfolio companies in our records.

Check size: $500K–$3.0M
Portfolio: 6 companies on record
Partners: 10 listed
Stage: Pre-Seed, Seed
Sectors: Healthcare, Other, AI / ML, Developer Tools
HQ: Austin, TX
AUM: Not in our records

Last verified: 2026-08-12

How to approach: warm intro preferred

Stage

Pre-Seed, Seed

Check Size

$500K – $3.0M

Portfolio

6+ companies

Team

10 partners

Investor activity

Investments in last 12 months: 0

Investment Thesis

Biolumina Ventures focuses on early-stage biotech startups that are leveraging cutting-edge AI and data analytics to transform drug discovery processes.

How Biolumina Ventures invests

Biolumina Ventures is a vc firm based in Austin, TX. The firm invests at the Pre-Seed, Seed stages, with a focus on Healthcare, Other, AI / ML, Developer Tools. It does not invest in Consumer.

Biolumina Ventures typically writes checks of $500K–$3.0M per investment.

Biolumina Ventures has backed 6 companies in our records, including Genomify, Surge Therapeutics, Enveda Biosciences.

Partners & Team

Chelsea Tholen

Senior Vice President, Account Supervisor

Cait Marconi

Vice President of Strategy

Lauren Bradley

Vice President of Project Management

Terry Mcshane

Associate Creative Director

Austin Wei

Executive Creative Director

Stevenson Hawkey

Senior Vice President, Account Supervisor

Dr. Lisa Chen

Biotech

Drug Discovery

Kirsten Kantak

President and Chief Executive Officer

healthcare

diagnostics

therapy adoption

Passionate about using her curiosity to build knowledge—for herself and for everyone around her. She is driven by her awareness that the work we do helps ensure that HCPs, patients, and caregivers have the latest information about available treatments, giving them the opportunity to make the best choices.

Diane Iler-Smith

Chief Creative Officer

science

creativity

therapeutic innovation

Knows that curiosity is the glue that binds her two passions: science and creativity. For Diane, curiosity fuels a creative approach that addresses an important purpose—to share the latest scientific advances with the HCPs, patients, and caregivers who are making critical decisions about treatment.

Brenda Aske

Chief Strategy Officer

strategy

emerging technologies

innovation

Believes curiosity is a competitive advantage. She brings together people, ideas, and emerging technologies to challenge assumptions, connect dots others miss, and uncover new possibilities.

Industry Focus

Invests In

Healthcare

Other

AI / ML

Developer Tools

Does Not Invest In

Consumer

Portfolio Companies (6)

Other

Genomify

Biotech

Surge Therapeutics

Biotechnology / Oncology·Series B

Developing intraoperative immunotherapies using biodegradable hydrogels to prevent cancer recurrence.

Enveda Biosciences

Biotechnology / AI Drug Discovery·Series B1

Utilizing metabolomics and machine learning to discover novel small-molecule therapeutics.

Candid Therapeutics

Biotechnology / Immunology·Series A / Launch

Developing multi-specific T-cell engagers to deplete B-cells for autoimmune disease treatment.

Capstan Therapeutics

Biotechnology / Cell & Gene Therapy·Series B

Developing in vivo CAR-T therapies using a targeted lipid nanoparticle platform.

ReCode Therapeutics

Biotechnology / Genetic Medicine·Series B Extension

Developing tissue-specific genetic medicines using a Selective Organ Targeting lipid nanoparticle platform.

How to pitch Biolumina Ventures

•Raising at Pre-Seed, Seed? You're squarely in their sweet spot.
•Lead with your fit in Healthcare, Other, AI / ML — the sectors they actively back.
•Size your ask to their typical $500K – $3.0M check.
•warm intro preferred
•Address your outreach to a specific partner, such as Chelsea Tholen, Senior Vice President, Account Supervisor.
•A warm introduction beats a cold email. Get matched and request an intro.